Eli Lilly and Company is developing its tirzepatide in heart failure and sleep apnea, in addition to obesity, in an effort to overcome payer resistance to covering drugs for weight loss, Lilly diabetes president Mike Mason explained during the company’s recent earnings presentation.
Medicare Coverage For Lilly’s Tirzepatide Could Be ‘Unlocked’ With Heart Failure, Apnea Claims
The problem that obesity drugs are not covered by Medicare Part D might be alleviated if Lilly’s weight loss candidate is also cleared for indications that are reimbursed. Policy and treatment experts discuss the importance of proving obesity drugs can lower federal government health care spending during a recent discussion convened by the Institute for Clinical and Economic Review.
More from Market Access
• By
Eli Lilly is seeking an injunction barring a weight loss clinic from dispensing modified versions of its GLP-1 products.
• By
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.
• By
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
As CMS administrator, Mehmet Oz will oversee the second cycle of Medicare drug price negotiations and Part D redesign issues, but will have experienced deputies to help.
More from Pink Sheet
• By
Most, if not all, adcomm support staff in the drug and biologic centers who handled meeting-specific tasks have been laid off, although sponsors still are preparing for the public reviews. Meanwhile, some cut FDA employees are being called back to work for "continuity of operations activities."
• By
Product reviews for drugs, biologics, devices, tobacco and foods could be consolidated into one office at the FDA, as part of a restructuring plan circulating that was obtained by Pink Sheet.
• By
Pink Sheet reporter and editors discuss how the massive layoffs will reshape the FDA and its impact on the drug and biologics industries.